1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

KKPCF
Kaken Pharmaceutical Co., Ltd.US flagOther OTC
26.00
USD
- -
- -
984.58MMarket Cap
Kaken Pharmaceutical Co., Ltd.
KKPCF
(Other OTC)

Recent

price

26.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,737.07
1,849.37
1,964.66
2,000.11
2,085.68
2,253.14
2,637.29
2,486.25
2,432.22
2,361.61
2,279.87
1,942.96
2,002.05
1,942.56
1,909.23
2,464.13
947.34
Revenue per Share
137.57
175.73
184.91
206.59
228.27
290.88
510.54
536.71
470.55
445.78
494.89
347.37
251.44
144.79
212.67
365.42
104.5
Basic EPS, GAAP
172.1
172.37
173.17
179.57
270.52
304.97
575.91
316.24
489.62
476.53
645.53
313.4
265.39
187.56
10.87
665.28
- -
Free Cash Flow per Basic Share
56.08
66.07
76.2
84.19
92.29
102.3
131.92
153.28
150.36
150.5
150.64
150.58
150.46
150.36
149.92
188.62
- -
Dividend per Share
1,073.32
1,233.7
1,396.01
1,559.02
1,726.76
1,842.56
2,232.68
2,637.22
2,993.25
3,333.25
3,544.25
3,791.53
3,954.92
3,992.12
4,037.66
4,168.98
4,325.72
Book Value per Share
1,209.12
1,283.34
1,364.28
1,512.95
1,582.65
1,838.7
2,161.23
2,493.35
2,800.12
3,024
3,271.67
3,514.67
3,425.33
3,462.62
3,611.89
3,494.22
3,882.75
Tangible Book Value per Share
49
47
45
44
43
42
41
41
40
40
39
39
38
38
38
38
38
Basic Weighted Avg Shares
85,026
86,433
87,994
87,047
88,949
93,895
109,218
101,991
98,432
94,167
89,234
74,979
76,034
72,984
72,044
94,035
35,873
Sales/Revenue/Turnover
18.28
21.09
17.26
16.79
17.85
21.97
32.19
30.11
27.94
26.12
29.71
23.73
22.45
10.96
13.21
22.37
11.16
Operating Margin (%)
2,423
2,488
2,424
2,607
2,538
2,400
2,242
1,937
2,124
2,153
2,312
2,318
2,486
2,568
2,753
2,554
- -
Depreciation Expense
6,734
8,213
8,282
8,991
9,735
12,122
21,143
22,017
19,043
17,775
19,370
13,405
9,549
5,440
8,025
13,945
3,957
Net Income, GAAP
38.37
39.37
43.13
36.58
37.18
34.86
40.09
29.19
31.22
28.68
27.16
28.15
31.23
20.2
18.07
28.25
4.35
Effective Tax Rate (%)
7.92
9.5
9.41
10.33
10.94
12.91
19.36
21.59
19.35
18.88
21.71
17.88
12.56
7.45
11.14
14.83
11.03
Profit Margin (%)
27,966
25,419
26,860
26,751
30,445
38,647
55,130
66,474
72,458
76,151
86,681
92,386
91,564
89,065
87,950
81,023
98,998
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
59,575
60,375
62,070
66,577
68,094
77,098
89,874
102,654
113,873
121,130
128,467
136,256
138,323
136,835
143,755
152,634
154,404
Total Equity
13.81
15.4
11.74
12.18
12.96
16.54
22.3
20.52
16.28
13.93
14.62
9.21
8.18
4.45
5.37
9.69
2.47
Return on Invested Capital (%)
11.51
12.96
12.12
12.25
12.64
15.14
23.68
21.14
16.07
13.59
13.88
9.17
6.27
3.53
5.18
8.75
2.46
Return on Capital (%)
13.32
14.91
13.78
13.79
13.76
16.12
24.98
21.95
16.61
13.99
14.26
9.41
6.44
3.62
5.31
8.95
2.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
3,850
- -
3,850
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
- -
38
Market Capitalization
- -
- -
149,683

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
106,974
- -
122,681
Cash, Cash Equivalents & STI
65,324
- -
83,986
Accounts Receivable, Net
23,744
- -
21,024
Inventories
17,167
- -
16,861
Total Current Liabilities
19,024
- -
23,683
Payables & Accruals
- -
- -
- -
ST Debt
3,850
- -
3,850
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.19%
3.55%
6.18%
Free Cash Flow
602.28%
1,179.83%
6,092.2%
Net Income, GAAP
8.6%
3.74%
73.77%
Sales/Revenue/Turnover
0.73%
2.13%
30.52%
Total Cash Common Dividend
6%
4.63%
27.24%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18,150
18,021
18,514
17,359
72,044
2025
- -
- -
- -
- -
94,035
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
66.98
- -
- -
- -
212.67
2025
- -
- -
- -
- -
365.42
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
149.92
2025
- -
- -
- -
- -
188.62
2026
- -
- -
- -
- -
- -
Similar Companies
Anhui Huangshan Capsule Co., Ltd. (002817.SZ)
YourWay Cannabis Brands Inc. (YOURF)
Jupiter Wellness, Inc. (JUPW)
Radiko Holdings Corp. (GEATF)
Hikma Pharmaceuticals PLC (HKMPY)
China SXT Pharmaceuticals, Inc. (SXTC)
Business
Kaken Pharmaceutical Co., Ltd. develops, manufactures and markets prescription pharmaceuticals, medical devices, agrochemicals and engages in real estate operations primarily in Japan. The company offers core pharmaceutical products including Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock, a treatment for primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; and Hernicore, a treatment for lumbar disc herniation; as well as the medical device Seprafilm, a post-operative adhesion barrier. It focuses on therapeutic areas such as dermatology, orthopedics, ophthalmology and wound care, serving healthcare professionals and patients through prescription channels, while its agrochemical segment provides fungicides, paddy rice herbicides and feed additives. Founded in 1948 from the reorganization of the Institute of Physical and Chemical Research (Riken) and headquartered in Tokyo, Japan, Kaken Pharmaceutical maintains a collaboration and licensing agreement with Alumis Inc. to develop, manufacture and commercialize ESK-001, a selective oral tyrosine kinase 2 inhibitor for dermatology indications in Japan. In December 2024, the company entered a purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for approximately $100 million, marking a strategic expansion into new assets. Under its Long-Term Business Plan 2031 launched in 2022, Kaken pursues global growth in dermatology and orthopedics through enhanced research, overseas expansion and operational transformation, with pharmaceuticals comprising over 96% of consolidated net sales complemented by stable real estate income from Bunkyo Green Court.